Who
Linda Burkly
EVP, Chief Scientific Officer
Company insider
Files Form 4 as: EVP, Chief Scientific Officer, Editas Medicine.
In numbers
- Trades disclosed
- 23
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $124K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 24 Jul 2023
- Last trade
- 3 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 4 Sep 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $2,153709 at $3.04 | filing |
| 3 Sep 2026filed 4 Sep 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $2,155709 at $3.04 | filing |
| 28 Jul 2026filed 29 Jul 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $13K4,928 at $2.67 | filing |
| 28 Jul 2026filed 29 Jul 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $13K4,928 at $2.67 | filing |
| 3 Jun 2026filed 5 Jun 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,975731 at $2.70 | filing |
| 3 Jun 2026filed 5 Jun 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,974731 at $2.70 | filing |
| 12 Mar 2026filed 16 Mar 2026 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —292,856 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —292,856 at $0.00 | filing |
| 3 Mar 2026filed 4 Mar 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,513749 at $2.02 | filing |
| 3 Mar 2026filed 4 Mar 2026 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,513749 at $2.02 | filing |
| 3 Dec 2025filed 4 Dec 2025 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,533713 at $2.15 | filing |
| 3 Sep 2025filed 4 Sep 2025 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,846710 at $2.60 | filing |
| 31 Jul 2025filed 4 Aug 2025 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $13K5,121 at $2.49 | filing |
| 3 Jun 2025filed 4 Jun 2025 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $1,249726 at $1.72 | filing |
| 8 Mar 2025filed 27 Mar 2025 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —275,100 at $0.00 | filing |
| 8 Mar 2025filed 27 Mar 2025 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 4 Mar 2025filed 5 Mar 2025 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $4,9442,891 at $1.71 | filing |
| 25 Jul 2024filed 26 Jul 2024 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $64K11,886 at $5.42 | filing |
| 2 Mar 2024filed 5 Mar 2024 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —74,400 at $0.00 | filing |
| 2 Mar 2024filed 5 Mar 2024 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Code A | —24,800 at $0.00 | filing |
News
Financial Contrast: Alvotech (NASDAQ:ALVO) & Editas Medicine (NASDAQ:EDIT)EDIT · themarketsdaily.com · 18 Oct 2026Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor ConferenceEDIT · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Linda Burkly; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.